Kalaris Therapeutics Inc Dossier
Valuation
How Intrinsic Value compares with model outputs
Intrinsic Value Insufficient data for a value estimatebased on filings through 30 Jun 2026
Market Price $2.85Price as of 1 Oct 2026
Data confidenceNot applicable
Valuation methods vs. Market Price
$0$4$8$12$16$20
DCF
Insufficient data for this method
abstainedDNI
Loss-making, earnings methods not applicable
abstainedP/S
Missing revenue base
abstainedP/E
Negative earnings base
abstainedP/B
$18.10◇ $12.04
PEG
No own multiple history
abstained$0$4$8$12$16$20
Market Price ($2.85) Intrinsic Value peer-implied value
Company vs. peer median Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.
Assumptions
| Parameter | Value |
|---|---|
| Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 5.5%/yr (balance of the path). | 5.4% per year |
Years 6–10: glide to demonstrated growthPer-year ratesYr 65.4%Yr 75.4%Yr 85.4%Yr 95.4%Yr 105.4% | 5.5% → 5.4% |
Years 11–20: glide to long-run ratePer-year ratesYr 115.1%Yr 124.9%Yr 134.7%Yr 144.4%Yr 154.2%Yr 163.9%Yr 173.7%Yr 183.5%Yr 193.2%Yr 203.0% | 5.4% → 3.0% |
| Beyond year 20: terminal growthPerpetual long-run rate | 3.0% |
| Discount rate (cost of equity) | 7.0% |
| Volatility vs market (adjusted beta) | 0.45 |
Valuation Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.
Compare with peers
Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.
Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.
Best in rowHigher is betterLower is better—Data not available
Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.